Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Alexa R HospodarKenneth J SmithYuting ZhangInmaculada HernandezPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2019)
The comparative cost effectiveness of edoxaban and warfarin is highly sensitive to TTR. At the $US100,000/QALY willingness-to-pay threshold, our results suggest that warfarin is the most cost-effective treatment for patients who can achieve a TTR of 70%.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- left atrial
- catheter ablation
- left atrial appendage
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- venous thromboembolism
- percutaneous coronary intervention
- peritoneal dialysis
- prognostic factors
- molecularly imprinted
- smoking cessation
- mitral valve
- living cells